Ramin Farzaneh-Far, M.D.

Ramin is a Venture Partner at Raven, RA Capital’s healthcare incubator, where he collaborates with RA Capital’s investment team to evaluate drug discovery platforms and initiate novel therapeutics programs. He previously served as Chief Medical Officer of Capstan Therapeutics (acquired by AbbVie in 2025) and Ra Pharmaceuticals (acquired by UCB in 2020). Ramin is an experienced clinical trialist and has led global clinical development programs at Akebia Therapeutics and Gilead Sciences. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF), and the University of Texas Southwestern Medical Center. He completed his internal medicine residency at Brigham and Women’s Hospital in Boston and trained in cardiovascular medicine at UCSF.

He holds B.A. and M.A. degrees in immunology from the University of Cambridge, an M.D. from University College London, and a Master of Advanced Study in Clinical Research from UCSF.